A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer
- 5 January 2024
- journal article
- research article
- Published by Springer Nature in Journal of Mathematical Biology
- Vol. 88 (2) , 1-20
Abstract
This study presents a new framework for obtaining personalized optimal treatment strategies targeting aberrant signaling pathways in esophageal cancer, such as the epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) signaling pathways. A new pharmacokinetic model is developed taking into account specific heterogeneities of these signaling mechanisms. The optimal therapies are designed to be obtained using a three step process. First, a finite-dimensional constrained optimization problem is solved to obtain the parameters of the pharmacokinetic model, using discrete patient data measurements. Next, a sensitivity analysis is carried out to determine which of the parameters are sensitive to the evolution of the variants of EGF receptors and VEGF receptors. Finally, a second optimal control problem is solved based on the sensitivity analysis results, using a modified pharmacokinetic model that incorporates two representative drugs Trastuzumab and Bevacizumab, targeting EGF and VEGF, respectively. Numerical results with the combination of the two drugs demonstrate the efficiency of the proposed framework.Keywords
Funding Information
- National Science Foundation (2212938)
- Interdisciplinary Research Program, UTA
- Interdisciplinary Research Program, UTA (2021-772)
This publication has 39 references indexed in Scilit:
- A Fokker–Planck control framework for multidimensional stochastic processesJournal of Computational and Applied Mathematics, 2013
- Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational OncologyBiotechnology Advances, 2012
- Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypesClinical and Experimental Immunology, 2011
- Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cellsCell Death & Disease, 2010
- BevacizumabThe Oncologist, 2010
- Orai1 and STIM1 Are Critical for Breast Tumor Cell Migration and MetastasisCancer Cell, 2009
- A methodology for performing global uncertainty and sensitivity analysis in systems biologyJournal of Theoretical Biology, 2008
- Sampling and sensitivity analyses tools (SaSAT) for computational modellingTheoretical Biology and Medical Modelling, 2008
- Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002